Get to know our clinical trials

Clinical trial of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma.

THE MAIN OBJECTIVE OF THIS STUDY IS TO COMPARE THE EFFICACY OF ELRANATAMAB (GROUP A) VERSUS LENALIDOMIDE (GROUP B) IN PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA (MM) AND WHO HAVE POSITIVE MINIMAL RESIDUAL DISEASE (MRD) (STILL HAVE MYELOMA CELLS PRESENT IN THEIR BONE MARROW) AFTER UNDERGOING AUTOLOGOUS (CELLS/TISSUE THAT HAVE BEEN OBTAINED FROM THEIR BODY) STEM CELL TRANSPLANTATION (ASCT). THE AIM IS TO ASSESS WHETHER THE STUDY DRUG, ELRANATAMAB, CAN PROVIDE BETTER CLINICAL BENEFIT AS A MAINTENANCE TREATMENT COMPARED TO LENALIDOMIDE.

Imagen de la Dra. Paula Rodríguez Otero, especialista de Hematología
Dr. Paula Rodríguez Otero Curriculum
Specialist Haematology and Haemotherapy Department
Navarre headquarters
Madrid headquarters
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • RANDOMIZED, TWO-ARM, PHASE III STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO HAVE MINIMAL RESIDUAL DISEASE AFTER UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION. IMMUNOTHERAPY
  • Code EudraCT: 2021-006052-14
  • Protocol number: C1071007
  • Promoter: Pfizer
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.